INtraveNous and Oral administration of elinogrel to eVAluate Tolerability and Efficacy in nonurgent PCI patients - INNOVATE PCI


The goal of the trial was to evaluate treatment with the intravenous (IV) and oral P2Y12 receptor inhibitor (elinogrel) compared with clopidogrel during nonurgent percutaneous coronary intervention (PCI). Elinogrel is a direct acting reversible agent, which competitively binds to the P2Y12 receptor. This is a phase 2b dose-finding study for elinogrel.